English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/205577
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells

AuthorsMascaraque, Marta; Delgado-Wicke, Pablo; Nuevo-Tapioles, Cristina CSIC ORCID; Gracia-Cazaña, Tamara; Abarca-Lachen, Edgar; González, Salvador; Cuezva, José M. CSIC ORCID; Gilaberte, Yolanda; Juarranz, Ángeles
KeywordsBasal cell carcinoma
Photodynamic therapy
Resistance
Metabolic markers
Metformin
Issue Date13-Mar-2020
PublisherMultidisciplinary Digital Publishing Institute
CitationCancers 12(3): 668 (2020)
AbstractPhotodynamic Therapy (PDT) with methyl-aminolevulinate (MAL-PDT) is being used for the treatment of Basal Cell Carcinoma (BCC), although resistant cells may appear. Normal differentiated cells depend primarily on mitochondrial oxidative phosphorylation (OXPHOS) to generate energy, but cancer cells switch this metabolism to aerobic glycolysis (Warburg effect), influencing the response to therapies. We have analyzed the expression of metabolic markers (β-F1-ATPase/GAPDH (glyceraldehyde-3-phosphate dehydrogenase) ratio, pyruvate kinase M2 (PKM2), oxygen consume ratio, and lactate extracellular production) in the resistance to PDT of mouse BCC cell lines (named ASZ and CSZ, heterozygous for ptch1). We have also evaluated the ability of metformin (Metf), an antidiabetic type II compound that acts through inhibition of the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway to sensitize resistant cells to PDT. The results obtained indicated that resistant cells showed an aerobic glycolysis metabolism. The treatment with Metf induced arrest in the G0/G1 phase and a reduction in the lactate extracellular production in all cell lines. The addition of Metf to MAL-PDT improved the cytotoxic effect on parental and resistant cells, which was not dependent on the PS protoporphyrin IX (PpIX) production. After Metf + MAL-PDT treatment, activation of pAMPK was detected, suppressing the mTOR pathway in most of the cells. Enhanced PDT-response with Metf was also observed in ASZ tumors. In conclusion, Metf increased the response to MAL-PDT in murine BCC cells resistant to PDT with aerobic glycolysis.
Description© 2020 by the authors.
Publisher version (URL)https://doi.org/10.3390/cancers12030668
URIhttp://hdl.handle.net/10261/205577
DOIhttp://dx.doi.org/10.3390/cancers12030668
E-ISSN2072-6694
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
Metformin_Mascaraque_Art2020.pdf4,14 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.